Zhongyao Jia

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

Lin Wang, Xuezhi Hao, Yanrong Hao, Yanping Hu et autres

cn, hk (code pays fourni par la source)

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial

Changgong Zhang, Jianhua Chen, Huijuan Wu, Jun Wang et autres

Background: Currently, the need for new therapeutic strategies involving programmed cell death protein-1 (PD-1) monoclonal antibodies in the second-line setting of small cell lung cancer (SCLC) is urgent. This study aimed to evaluate the efficacy and safety of anlotinib plus penpulimab as …

cn (code pays fourni par la source)

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Caicun Zhou, Yanping Hu, Ekaterine Arkania, Saadettin Kılıçkap et autres

cn, ge, tr, us (code pays fourni par la source)

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

Changgong Zhang, Sheng Yang, Jianhua Chen, Huijuan Wu et autres

8568 Background: Combined therapy of an immune checkpoint inhibitor with a targeted anti-angiogenic agent had been proved to be effective for lung cancer. Penpulimab (AK105) was engineered to eliminate FcγR binding and antibody-dependent cell-mediated cytotoxicity (ADCC)/ antibody-dependent celluar phagocytosis (ADCP) completely, where …

cn (code pays fourni par la source)

Multi-center randomized trial of Compound Kushen injection for decreasing radiation- induced thoracic toxicity in lung cancer patients

Qingxi Yu, Jun Wang, Fan Wang, Haitao Yin et autres

Abstract Background: Thoracic radiation therapy plays an important role in the treatment of inoperable lung cancer. However, radiotherapy-induced toxicity poses an important challenge for radiation oncologists. Research has shown that Compound Kushen Injection (CKI) has anti-inflammatory activity and can reduce toxicity when …

cn, gb (code pays fourni par la source)

Circular RNA circ_0020123 Promotes Non-Small Cell Lung Cancer Progression Through miR-384/TRIM44 Axis

Qingshan Ma, Baogang Huai, Yuting Liu, Zhongyao Jia et autres

Background: It was reported that circular RNAs (circRNAs) and microRNAs (miRNAs) were related to non-small cell lung cancer (NSCLC) development. However, the detailed mechanisms of circ_0020123 and miR-384 in NSCLC are elusive. Methods: QRT-PCR and Western blot assay were performed to detect …

cn (code pays fourni par la source)

Multi-Center Randomized Trial of Compound Kushen Injection for Decreasing Radiation- Induced Thoracic Toxicity in Lung Cancer Patients

Qingxi Yu, Jun Wang, Fan Wang, Haitao Yin et autres

Abstract Background: Thoracic radiation therapy plays an important role in the treatment of inoperable lung cancer. However, radiotherapy-induced toxicity poses an important challenge for radiation oncologists. Research has shown that Compound Kushen Injection (CKI) has anti-inflammatory activity and can reduce toxicity when …

cn (code pays fourni par la source)

Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer

Yunpeng Yang, Bin Wu, Linian Huang, Meiqi Shi et autres

Background: Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative therapy for cancer patients. Methods: In this randomized, …

cn, us (code pays fourni par la source)

Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma

Haiying Peng, Shaobo Yao, Qingyu Dong, Yanxia Zhang et autres

Excision repair cross-complementing group 1 (ERCC1) functions as a nucleotide excision repair (NER) enzyme. Altered ERCC1 expression or function is closely associated with cancer development and progression. This study determined the association of ERCC1 expression with survivin expression, clinicopathological characteristics, and survival …

cn (code pays fourni par la source)

Sirtuin 2 (Sirt2) Expression Predicts Lymph Node Metastasis and Poor Overall Survival of Patients with Esophageal Squamous Cell Carcinoma

Yan Li, Xuemei Zhan, Zhongyao Jia, Lili Liu et autres

BACKGROUND: Altered expression of Sirtuin 2 (Sirt2) was associated with cancer development and progression. This study further assessed the association of Sirt2 expression with clinicopathological data and prognosis of patients with esophageal squamous cell carcinoma (ESCC) after postoperative concurrent chemoradiotherapy. METHODS: Tissue …